Tumour lysate particle only vaccine - Orbis Health Solutions
Alternative Names: TLPO vaccineLatest Information Update: 21 Dec 2023
At a glance
- Originator Orbis Health Solutions
- Developer Cancer Insight; Elios Therapeutics
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Malignant melanoma
Most Recent Events
- 29 Nov 2023 Phase-II clinical trials in Solid tumours (Second-line therapy or greater, Early-stage disease, Late-stage disease, Adjunctive treatment) in USA (Intradermal) (NCT06175221)
- 30 Mar 2021 Phase-I/II trial is still ongoing for Malignant melanoma (In adults, In the elderly, Late-stage disease, Prevention of relapse) in USA (Parenteral) (NCT02301611)
- 04 Jan 2019 Tumour lysate, particle only (TLPO) vaccine licensed to Perseus